找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Chronic Myeloid Leukemia; Rüdiger Hehlmann Book 2021Latest edition The Editor(s) (if applicable) and The Author(s), under exclusive licens

[復(fù)制鏈接]
查看: 49318|回復(fù): 63
樓主
發(fā)表于 2025-3-21 17:32:24 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Chronic Myeloid Leukemia
編輯Rüdiger Hehlmann
視頻videohttp://file.papertrans.cn/227/226397/226397.mp4
概述Presents state-of-the-art reviews of key issues relating to chronic myeloid leukemia.Covers a wide range of management topics.Discusses prognostic aspects and early response prediction.Examines the ch
叢書名稱Hematologic Malignancies
圖書封面Titlebook: Chronic Myeloid Leukemia;  Rüdiger Hehlmann Book 2021Latest edition The Editor(s) (if applicable) and The Author(s), under exclusive licens
描述.This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib.?.
出版日期Book 2021Latest edition
關(guān)鍵詞Chronic myeloid leukaemia; BCR-ABL; Tyrosine kinase inhibitors; Philadelphia chromosome; Fertility; Hemat
版次2
doihttps://doi.org/10.1007/978-3-030-71913-5
isbn_softcover978-3-030-71915-9
isbn_ebook978-3-030-71913-5Series ISSN 2197-9766 Series E-ISSN 2197-9774
issn_series 2197-9766
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱Chronic Myeloid Leukemia影響因子(影響力)




書目名稱Chronic Myeloid Leukemia影響因子(影響力)學(xué)科排名




書目名稱Chronic Myeloid Leukemia網(wǎng)絡(luò)公開度




書目名稱Chronic Myeloid Leukemia網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Chronic Myeloid Leukemia被引頻次




書目名稱Chronic Myeloid Leukemia被引頻次學(xué)科排名




書目名稱Chronic Myeloid Leukemia年度引用




書目名稱Chronic Myeloid Leukemia年度引用學(xué)科排名




書目名稱Chronic Myeloid Leukemia讀者反饋




書目名稱Chronic Myeloid Leukemia讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:15:15 | 只看該作者
The Biology and Pathogenesis of Chronic Myeloid Leukaemia,he discovery of the Philadelphia (Ph) chromosome. This genomic abnormality is the result of a t(9;22) translocation, leading to the fusion oncogene, .. The resulting protein is capable of hijacking a vast repertoire of cellular functions that drive myeloid hyperplasia, characteristic of the initial,
板凳
發(fā)表于 2025-3-22 01:11:12 | 只看該作者
Epidemiology of Chronic Myeloid Leukaemia,r epidemiological research. CML registries with a more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7–1.3/100,000, median age at di
地板
發(fā)表于 2025-3-22 08:27:19 | 只看該作者
5#
發(fā)表于 2025-3-22 09:56:43 | 只看該作者
6#
發(fā)表于 2025-3-22 14:53:36 | 只看該作者
7#
發(fā)表于 2025-3-22 17:38:03 | 只看該作者
8#
發(fā)表于 2025-3-23 01:12:07 | 只看該作者
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia: 2021 Update,d to define time-related clinical milestones as well as eligibility for stopping treatment. To improve the comparability of molecular monitoring results between centers, an international scale (IS) for . measurement has been implemented by testing laboratories worldwide, either by the derivation of
9#
發(fā)表于 2025-3-23 03:50:14 | 只看該作者
10#
發(fā)表于 2025-3-23 06:39:27 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 04:22
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
缙云县| 台安县| 莱阳市| 兴城市| 昂仁县| 闵行区| 佛山市| 上高县| 南木林县| 太原市| 威远县| 固原市| 宜都市| 柘城县| 仙游县| 特克斯县| 上思县| 巴彦淖尔市| 三穗县| 任丘市| 汾阳市| 滨海县| 读书| 二连浩特市| 唐海县| 方山县| 阿拉善左旗| 洞头县| 清原| 当雄县| 眉山市| 河曲县| 灵山县| 安顺市| 文成县| 措美县| 广安市| 丹江口市| 白朗县| 邯郸市| 定安县|